Anti-ganglioside antibodies and the presynaptic motor nerve terminal

Annals of the New York Academy of Sciences

Volumn 1132, Issue , 2008, Pages 114-123

  Willison, Hugh J ^a   Plomp, Jaap J ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibody; Complement; Ganglioside; Guillain Barr syndrome; Miller Fisher syndrome; Motor nerve terminal; Peripheral neuropathy; Perisynaptic Schwann cells; Synaptic transmission

Indexed keywords

GANGLIOSIDE ANTIBODY; GLYCOSYLTRANSFERASE; OLIGOSACCHARIDE;

CAMPYLOBACTER JEJUNI; CONFERENCE PAPER; GUILLAIN BARRE SYNDROME; IMMUNOLOGICAL TOLERANCE; KNOCKOUT MOUSE; MOLECULAR MIMICRY; NERVE ENDING; NEUROMUSCULAR TRANSMISSION; NEUROPATHY; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PHENOTYPE; SYNAPTOSOME;

CAMPYLOBACTER JEJUNI; MURINAE; MUS;

EID: 45249122484     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1405.010     Document Type: Conference Paper

References (52)

1. Hughes, R.A. & D.R. Cornblath. 2005. Guillain-Barre syndrome. Lancet 366 : 1653 1666.
2. Willison, H.J. & N. Yuki. 2002. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125 : 2591 2625.
3. Sandhoff, K. & T. Kolter. 2003. Biosynthesis and degradation of mammalian glycosphingolipids. Philos. Trans. R. Soc. Lond B Biol. Sci. 358 : 847 861.
4. Fisher, M. 1956. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N. Engl. J. Med. 255 : 57 65.
5. Chiba, A., S. Kusunoki, T. Shimizu & I. Kanazawa. 1992. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann. Neurol. 31 : 677 679.
6. Buchwald, B., J. Bufler, M. Carpo, et al. 2001. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology 56 : 67 74.
7. Chiba, A., S. Kusunoki, H. Obata, et al. 1997. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 745 : 32 36.
8. Bullens, R.W., G.M. O'Hanlon, E. Wagner, et al. 2002. Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J. Neurosci. 22 : 6876 6884.
9. Chamberlain, L.H., R.D. Burgoyne & G.W. Gould. 2001. SNARE proteins are highly enriched in lipid rafts in PC12 cells: implications for the spatial control of exocytosis. Proc. Natl. Acad. Sci. USA 98 : 5619 5624.
10. Lang, T., D. Bruns, D. Wenzel, et al. 2001. SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. EMBO J. 20 : 2202 2213.
11. Willison, H.J. & G.M. O'Hanlon. 1999. The immunopathogenesis of Miller Fisher syndrome. J. Neuroimmunol. 100 : 3 12.
12. Vincent, A., B. Lang & K.A. Kleopa. 2006. Autoimmune channelopathies and related neurological disorders. Neuron 52 : 123 138.
13. Lange, D.J., T. Deangelis & M.A. Sivak. 2006. Single-fiber electromyography shows terminal axon dysfunction in Miller Fisher syndrome: a case report. Muscle Nerve 34 : 232 234.
14. Lo, Y.L., T.H. Leoh, Y.F. Dan, et al. 2006. Presynaptic neuromuscular transmission defect in the Miller Fisher syndrome. Neurology 66 : 148 149.
15. Sartucci, F., G. Cafforio, D. Borghetti, et al. 2005. Electrophysiological evidence by single fibre electromyography of neuromuscular transmission impairment in a case of Miller Fisher syndrome. Neurol. Sci. 26 : 125 128.
16. Uncini, A. & A. Lugaresi. 1999. Fisher syndrome with tetraparesis and antibody to GQ1b: evidence for motor nerve terminal block. Muscle Nerve 22 : 640 644.
17. Wirguin, I., G. Ifergane, Y. Almog, et al. 2002. Presynaptic neuromuscular transmission block in Guillain-Barre syndrome associated with anti-GQ1b antibodies. Neuromuscul. Disord. 12 : 292 293.
18. Goodfellow, J.A., T. Bowes, K. Sheikh, et al. 2005. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J. Neurosci. 25 : 1620 1628.
19. Ortiz, N., R. Rosa, E. Gallardo, et al. 2001. IgM monoclonal antibody against terminal moiety of GM2, GalNAc-GD1a and GalNAc-GM1b from a pure motor chronic demyelinating polyneuropathy patient: effects on neurotransmitter release. J. Neuroimmunol. 119 : 114 123.
20. Roberts, M., H.J. Willison, A. Vincent & J. Newsom-Davis. 1995. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann. Neurol. 38 : 111 118.
21. Hughes, R.A.C. & J.H. Rees. 1997. Clinical and epidemiologic features of Guillain-Barre syndrome. J. Infect. Dis. 176 : S92 S98.
22. Odaka, M., N. Yuki & K. Hirata. 2001. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J. Neurol. Neurosurg. Psychiatry 70 : 50 55.
23. Willison, H.J. & J. Veitch. 1994. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J. Neuroimmunol. 50 : 159 165.
24. Yuki, N. 2001. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect. Dis. 1 : 29 37.
25. Goodyear, C.S., G.M. O'Hanlon, J.J. Plomp, et al. 1999. Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J. Clin. Invest. 104 : 697 708.
26. Simons, K. & E. Ikonen. 1997. Functional rafts in cell membranes. Nature 387 : 569 572.
27. Willison, H.J. 2005. Ganglioside complexes: new autoantibody targets in Guillain-Barre syndromes. Nat. Clin. Pract. Neurol. 1 : 2 3.
28. Plomp, J.J., P.C. Molenaar, G.M. O'Hanlon, et al. 1999. Miller Fisher anti-GQ1b antibodies: a-latrotoxin-like effects on motor end plates. Ann. Neurol. 45 : 189 199.
29. Roberts, M., H. Willison, A. Vincent & J. Newsom-Davis. 1994. Serum factor in Miller-Fisher variant of Guillain-Barre syndrome and neurotransmitter release. Lancet 343 : 454 455.
30. Rohou, A., J. Nield & Y.A. Ushkaryov. 2007. Insecticidal toxins from black widow spider venom. Toxicon 49 : 531 549.
31. Willison, H.J., G.M. O'Hanlon, G. Paterson, et al. 1996. A somatically mutated human anti-ganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18. J. Clin. Invest. 97 : 1155 1164.
32. Jacobs, B.C., G.M. O'Hanlon, R.W. Bullens, et al. 2003. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 126 : 2220 2234.
33. Bullens, R.W., G.M. O'Hanlon, C.S. Goodyear, et al. 2000. Anti-GQ1b antibodies and evoked acetylcholine release at mouse motor endplates. Muscle Nerve 23 : 1035 1043.
34. Davletov, B.A., O.G. Shamotienko, V.G. Lelianova, et al. 1996. Isolation and biochemical characterization of a Ca2+-independent alpha-latrotoxin-binding protein. J. Biol. Chem. 271 : 23239 23245.
35. O'Hanlon, G.M., J.J. Plomp, M. Chakrabarti, et al. 2001. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 124 : 893 906.
36. Paparounas, K., G.M. O'Hanlon, C.P. O'Leary, et al. 1999. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain 122 : 807 816.
37. Halstead, S.K., I. Morrison, G.M. O'Hanlon, et al. 2005. Anti-disialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctions. Glia 52 : 177 189.
38. Halstead, S.K., P.D. Humphreys, J.A. Goodfellow, et al. 2005. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann. Neurol. 58 : 203 210.
39. Halstead, S.K., G.M. O'Hanlon, P.D. Humphreys, et al. 2004. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 127 : 2109 2123.
40. O'Hanlon, G.M., P.D. Humphreys, R.S. Goldman, et al. 2003. Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain 126 : 2497 2509.
41. Taguchi, K., J. Ren, I. Utsunomiya, et al. 2004. Neurophysiological and immunohistochemical studies on Guillain-Barre syndrome with IgG anti-GalNAc-GD1a antibodies-effects on neuromuscular transmission. J. Neurol. Sci. 225 : 91 98.
42. Mizuno, M. & B.P. Morgan. 2004. The possibilities and pitfalls for anti-complement therapies in inflammatory diseases. Curr. Drug Targets. Inflamm. Allergy 3 : 87 96.
43. Gold, R., M. Stangel & M.C. Dalakas. 2007. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat. Clin. Pract. Neurol. 3 : 36 44.
44. Andersen, S.M., C.C. Ling, P. Zhang, et al. 2004. Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barre syndrome. Org. Biomol. Chem. 2 : 1199 1212.
45. Townson, K., J. Boffey, D. Nicholl, et al. 2007. Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies. Glycobiology 17 : 294 303.
46. Willison, H.J., K. Townson, J. Veitch, et al. 2004. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. Brain 127 : 680 691.
47. Kumlien, G., L. Ullstrom, A. Losvall, et al. 2006. Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion 46 : 1568 1575.
48. Hafer-Macko, C.E., K.A. Sheikh, C.Y. Li, et al. 1996. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann. Neurol. 39 : 625 635.
49. Lu, J.L., K.A. Sheikh, H.S. Wu, et al. 2000. Physiologic-pathologic correlation in Guillain-Barre syndrome in children. Neurology 54 : 33 39.
50. Putzu, G.A., D. Figarella-Branger, C. Bouvier-Labit, et al. 2000. Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barre syndrome. J. Neurol. Sci. 174 : 16 21.
51. Wanschitz, J., H. Maier, H. Lassmann, et al. 2003. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome. Brain 126 : 2034 2042.
52. Van Sorge, N.M., N. Yuki, M.D. Jansen, et al. 2007. Leukocyte and complement activation by GM1-specific antibodies is associated with acute motor axonal neuropathy in rabbits. J. Neuroimmunol. 182 : 116 123.